Prospective Multicenter Evaluation of the QuickNavi-Campylobacter Assay in Stool Specimens

A prospective multicenter study in Japan demonstrated that the QuickNavi-Campylobacter rapid antigen test shows high concordance with the FilmArray Gastrointestinal Panel for early diagnosis of Campylobacter infections, though its sensitivity declines in specimens collected six or more days after symptom onset.

The Gist

Imagine your stomach is a busy highway, and sometimes, a mischievous germ called Campylobacter decides to crash the party, causing a traffic jam that results in a stomach bug (gastroenteritis). To fix the traffic, doctors need to know exactly which germ is causing the problem.

This paper is about testing a new, super-fast "traffic camera" to catch this germ, compared against the old, slow, but very thorough "police investigation."

Here is the breakdown of the study in simple terms:

1. The Problem: The Old Way is Too Slow

For a long time, the only way to confirm if someone had Campylobacter was to take a stool sample and grow the bacteria in a lab.

• The Analogy: Think of this like trying to identify a suspect by waiting for them to grow a mustache. It's the "Gold Standard" (the most reliable method), but it takes days. By the time the mustache grows, the patient might already be sick for a week, and the doctor has to guess what medicine to give in the meantime.

2. The New Tool: The "QuickNavi" Camera

The researchers tested a new kit called QuickNavi-Campylobacter.

• The Analogy: This is like a high-tech facial recognition camera at an airport. You swipe the sample, wait about 15 minutes (roughly the time it takes to brew a cup of coffee), and it tells you immediately: "Yes, that's the germ" or "No, it's not." It's cheap, easy to use, and doesn't need a fancy lab.

3. The Big Test: The "Road Trip"

The researchers didn't just test this in one lab; they sent the "camera" to nine different hospitals and clinics across Japan (from big city hospitals to small local clinics). They tested 410 patients who had stomach bugs.

They compared the new "camera" (QuickNavi) against the "Gold Standard" (a very sensitive molecular test called FilmArray, which is like a super-powered DNA scanner).

4. The Results: How Good Was the Camera?

• When the patient was sick recently (within the first few days): The new camera was very good. It caught the germ about 80% of the time when the DNA scanner said it was there.
• When the patient had been sick for a long time (6+ days): The camera got a bit confused. Its accuracy dropped to 50%.
  • Why? Imagine the germ is a fugitive. In the first few days, they are loud and easy to spot. But after a week, they have packed their bags and left town (or their numbers have dropped so low that the camera can't see them). The DNA scanner is so sensitive it can still find the "footprints" of the fugitive, but the quick camera misses them.

5. The "False Alarms" and "Missed Suspects"

• False Positives: The camera said "Germ Found!" three times, but the DNA scanner said "Nope." Further checks showed the germ wasn't actually there. The camera was just seeing a shadow and mistaking it for a criminal.
• False Negatives: The camera said "No Germ," but the DNA scanner found it 24 times. Most of these were cases where the patient had been sick for a while, and the germ load was too low for the quick camera to detect.

6. The Bottom Line

The Verdict: The QuickNavi test is a great tool for the early days of an illness.

• If you go to the doctor on Day 1 or 2: This test is fast, cheap, and accurate enough to tell the doctor, "Yes, it's Campylobacter, let's treat it now."
• If you go on Day 7: The test might miss it, and you might need the more expensive, high-tech DNA test to be sure.

Why does this matter?
Most people with stomach bugs want answers now, not in three days. This new test allows doctors in regular clinics (even without fancy labs) to make quick decisions and help patients feel better faster, as long as they catch the bug early in the game.

Technical Summary

1. Problem Statement

• Clinical Need: Campylobacter species (primarily C. jejuni and C. coli) are the leading bacterial cause of acute gastroenteritis in industrialized countries. Rapid and accurate diagnosis is crucial for effective management.
• Limitations of Current Standards:
  • Stool Culture: Historically the gold standard, but it suffers from low sensitivity, requires specialized media and microaerophilic conditions, and has long turnaround times (days), limiting its clinical utility for immediate decision-making.
  • Molecular Panels (e.g., FilmArray GI Panel): While highly sensitive, these multiplex PCR assays are expensive, require specialized laboratory equipment, and are not universally available in all clinical settings.
• Gap: There is a need for a rapid, cost-effective, and accessible diagnostic tool that bridges the gap between slow culture and expensive molecular testing, specifically for early-stage diagnosis.

2. Methodology

• Study Design: A prospective, multicenter evaluation conducted in Japan between March 2024 and August 2025.
• Setting: Nine healthcare facilities, including five acute care hospitals and four clinics (covering both pediatric and adult populations).
• Participants: 410 patients with suspected infectious gastroenteritis were included in the final analysis (after excluding 12 from an initial 422 due to lack of specimens, inability to perform reference testing, or asymptomatic status).
• Test Methods:
  • Index Test: QuickNavi-Campylobacter (Denka Co., Ltd.), a rapid immunochromatographic antigen test. Results are available in ~15 minutes and interpreted visually by healthcare professionals at each site.
  • Reference Standard: FilmArray Gastrointestinal (GI) Panel (bioMérieux), a multiplex PCR assay.
    • Note: For facilities without immediate access, specimens were frozen (−30°C) and transported to the University of Tsukuba Hospital for testing.
  • Discordance Resolution: Specimens with discordant results (Ag+ vs. PCR− or Ag− vs. PCR+) underwent further evaluation using:
    • Campylobacter culture (AccuRate™ Skirrow Agar).
    • Species-specific PCR assays for C. jejuni, C. coli, and C. upsaliensis.
• Statistical Analysis: Calculated positive, negative, and total concordance rates with 95% confidence intervals (Clopper-Pearson method) and Cohen's kappa coefficient for agreement.

3. Key Contributions

• Real-World Multicenter Validation: Unlike previous single-center studies, this research validates the QuickNavi-Campylobacter assay across diverse settings (hospitals and clinics) and demographics (pediatric and adult).
• High-Sensitivity Reference Comparison: The study compares the antigen test against the FilmArray GI Panel (a highly sensitive molecular method) rather than just conventional culture, providing a more rigorous assessment of diagnostic accuracy.
• Temporal Analysis: The study specifically evaluates how diagnostic performance changes based on the time elapsed between symptom onset and specimen collection, a critical factor often overlooked in rapid test evaluations.
• Investigation of Discordance: The authors performed deep-dive analyses (culture + additional PCR) on discordant cases to investigate potential false positives and false negatives, offering insights into the limitations of both the antigen test and the reference standard.

4. Key Results

• Overall Concordance:
  • Positive Concordance: 79% (Agreement on positive cases).
  • Negative Concordance: 99% (Agreement on negative cases).
  • Total Concordance: 93%.
• Impact of Timing (Time from Symptom Onset):
  • Early Phase (< 6 days): The test performs well. Specifically, specimens collected within 1 day of onset showed an 83% positive concordance rate.
  • Late Phase (≥ 6 days): Diagnostic performance drops significantly. The positive concordance rate fell to 50% for specimens collected 6 or more days after symptom onset.
• Discordant Case Analysis (27 cases):
  • False Positives (Ag+, PCR−): 3 cases. All were negative by culture and additional PCR. However, 2 of these showed melting curve patterns associated with known FilmArray false positives, suggesting the antigen test might have been correct in some instances where the PCR was a false negative.
  • False Negatives (Ag−, PCR+): 24 cases. Among these, C. jejuni or C. coli were confirmed via culture (8 cases) or additional PCR (5 cases). This indicates the antigen test missed active infections, likely due to lower bacterial loads or antigen degradation in later stages of infection.

5. Significance and Conclusion

• Clinical Utility: The QuickNavi-Campylobacter assay demonstrates high specificity (99%) and good overall concordance, making it a valuable tool for ruling out infection or confirming it in the early stages of illness.
• Optimal Use Case: The assay is most effective when used early in the disease course (within 6 days of symptom onset). Its utility diminishes significantly in later stages, likely due to the natural decline in bacterial load and antigen concentration in stool.
• Infrastructure Independence: The test offers a rapid (15 min), equipment-free alternative to molecular panels, enabling timely clinical decisions in clinics and hospitals lacking advanced molecular diagnostic infrastructure.
• Limitations: The study notes potential observer bias in visual interpretation of test lines and the need for further evaluation of less common Campylobacter species. Additionally, the possibility of false positives in the reference PCR method suggests the true sensitivity of the antigen test might be slightly higher than calculated.

Final Verdict: The QuickNavi-Campylobacter rapid antigen test is a reliable, rapid diagnostic tool for the early detection of campylobacteriosis in a multicenter setting, particularly suitable for settings where molecular testing is unavailable, provided samples are collected promptly after symptom onset.